Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3-Reference-Cited by-同舟云学术

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Published:2024-04-10 Issue:11 Volume:42 Page:e23-e43
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Jaiyesimi Ishmael A.¹,Leighl Natasha B.²^ORCID,Ismaila Nofisat³^ORCID,Alluri Krishna⁴^ORCID,Florez Narjust⁵^ORCID,Gadgeel Shirish⁶^ORCID,Masters Gregory⁷^ORCID,Schenk Erin L.⁸^ORCID,Schneider Bryan J.⁹,Sequist Lecia¹⁰^ORCID,Singh Navneet¹¹^ORCID,Bazhenova Lyudmila¹²^ORCID,Blanchard Elizabeth¹³,Freeman-Daily Janet¹⁴^ORCID,Furuya Naoki¹⁵^ORCID,Halmos Balazs¹⁶^ORCID,Azar Ibrahim Hanna¹⁷^ORCID,Kuruvilla Sara¹⁸,Mullane Michael¹⁹,Naidoo Jarushka²⁰^ORCID,Reuss Joshua E.²¹^ORCID,Spigel David R.²²^ORCID,Owen Dwight H.²³^ORCID,Patel Jyoti D.²⁴^ORCID

Affiliation:

1. Corewell Health William Beaumont University Hospital, Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, MI

2. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

3. American Society of Clinical Oncology ASCO, Alexandria, VA

4. St Luke's Mountain States Tumor Institute, Boise, ID

5. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

6. Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI

7. Helen F. Graham Cancer Center and Research Institute, Newark, DE

8. University of Colorado Anschutz Medical Center, Aurora, CO

9. University of Michigan Health System, Ann Arbor, MI

10. Massachusetts General Hospital, Boston, MA

11. Postgraduate Institute of Medical Education and Research, Chandigarh, India

12. University of California San Diego Moores Cancer Center, San Diego, CA

13. Southcoast Centers for Cancer Care, New Bedford, MA

14. The ROS1ders, Seattle, WA

15. St Marianna University School of Medicine, Kawasaki, Japan

16. Montefiore Einstein Center for Cancer Care, Bronx, NY

17. IHA Hematology Oncology Consultants, Ypsilanti, MI

18. London Health Sciences Centre, London, ON, Canada

19. Aurora Cancer Care, Mount Pleasant, WI

20. Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

21. Georgetown University, Washington, DC

22. Sarah Cannon Research Institute, Nashville, TN

23. Ohio State University, Columbus, OH

24. Northwestern University, Chicago, IL

Abstract

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Ten new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/living-guidelines .

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.02746

Reference74 articles.

1. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

2. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

3. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3

4. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

5. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1;Drugs in Context;2024-07-19

2. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1;Journal of Clinical Oncology;2024-07-10

3. Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights;JCO Oncology Practice;2024-07

4. Sequential Treatment of Anti-Pd-L1 Therapy Prior to Anti-Vegfr2 Therapy Contributes to More Significant Clinical Benefits in Non-Small Cell Lung Cancer;2024